4D Molecular Therapeutics, Inc. (FDMT) vs OmniAb, Inc. (OABI)
- 4D Molecular Therapeutics, Inc. FDMT 12.14 −5.67%
- OmniAb, Inc. OABI 4.59 −2.96%
4D Molecular Therapeutics, Inc. and OmniAb, Inc. are both Biotechnology companies. 4D Molecular Therapeutics, Inc. and OmniAb, Inc. are of similar size ($711.0M and $687.7M). 4D Molecular Therapeutics, Inc. grew revenue faster over the last twelve months: 278,712.1% against 67.0%. OmniAb, Inc. has the higher net margin (−115.1% vs −194.7%) and the higher return on invested capital (−14.5% vs −186.9%). Across the 17 metrics below, OmniAb, Inc. leads on 10 and 4D Molecular Therapeutics, Inc. on 7.
Valuation
Profitability
| Metric | FDMT | OABI | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 98.28% | 65.16% |
| Operating margin | (214.24%) | (125.78%) | 0.00% |
| Net margin | (194.74%) | (115.12%) | 0.00% |
| Free cash flow margin | (169.51%) | (47.17%) | 0.00% |
| Return on equity | (43.25%) | (16.95%) | (56.36%) |
| Return on assets | (37.09%) | (15.11%) | (48.04%) |
| Return on invested capital | (186.91%) | (14.52%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack